What Is BPC 157 Same as BPC-157? (Peptide Name Explained)

What Is BPC 157 Same as BPC-157? (Peptide Name Explained)

If you've searched for regenerative peptides, you've probably noticed something confusing: some sources write "BPC 157" while others write "BPC-157." Same compound? Different versions? The answer is simpler than most assume—BPC 157 and BPC-157 are identical. They describe the same synthetic peptide derived from Body Protection Compound, with the same 15-amino-acid sequence and the same mechanism of action. The hyphen is a formatting choice, not a chemical distinction.

We've synthesized peptides at Real Peptides for years, and this naming inconsistency causes more confusion than any other aspect of peptide sourcing. Researchers assume the hyphen signals a modification or alternative formulation—it doesn't. This guide explains what BPC 157 actually is, why the naming varies, and what that means for sourcing high-purity research compounds.

What is BPC 157 same as BPC-157?

BPC 157 is the same as BPC-157—both names refer to the identical synthetic pentadecapeptide sequence derived from human gastric juice protein BPC. The hyphen is a stylistic formatting convention used interchangeably in scientific literature and commercial labeling, with no impact on molecular structure, bioavailability, or mechanism of action. Whether written with or without the hyphen, the compound contains the same 15 amino acids in the same sequence.

Why the naming confusion exists—and what it reveals about peptide sourcing

Most peptide name variations signal meaningful differences: acetylated vs non-acetylated forms, salt formulations (acetate vs arginate), or fragment variants. BPC 157 vs BPC-157 isn't one of those cases. The inconsistency stems from how different research groups originally published their findings—some used hyphens in compound identifiers, others didn't. Commercial suppliers adopted whichever format appeared in the studies they referenced, and both versions persisted. The real issue this exposes is standardization: if a supplier can't explain why they use one format over another, it suggests they may not control their own synthesis protocols or understand the compound's origin. This article covers the peptide's actual structure, what "Body Protection Compound" means, and how to verify you're sourcing the authentic sequence regardless of how it's written.

BPC 157 Chemical Structure and Origin

BPC 157 is a synthetic pentadecapeptide—a 15-amino-acid sequence—engineered from a larger protective protein isolated from human gastric juice. The parent compound, Body Protection Compound (BPC), was first identified in the 1990s by researchers at the University of Zagreb studying the stomach's natural cytoprotective mechanisms. BPC 157 represents a stabilized fragment of that protein, designed for research use because the full-length parent molecule degrades rapidly outside physiological conditions. The 15-amino-acid sequence is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. This exact sequence defines BPC 157—whether the name includes a hyphen or not, the molecular structure remains identical.

The "157" designation references the compound's identification number within the original BPC research series conducted at Zagreb, not a molecular weight or fragment position. Some researchers mistakenly assume "157" indicates 157 daltons or the 157th amino acid in a parent chain—it doesn't. It's an arbitrary cataloging number from the lab that first synthesized and tested the peptide in animal models during the mid-1990s. Understanding this origin is critical when sourcing: any supplier claiming "BPC-157" is a "newer" or "improved" version compared to "BPC 157" is either uninformed or deliberately misleading. The sequence, mechanism, and research profile are identical.

Bioavailability and stability depend on synthesis quality, not naming convention. Small-batch peptide synthesis with exact amino-acid sequencing—like what Real Peptides performs—ensures each batch matches the published 15-amino-acid sequence precisely. Variations in purity, lyophilization technique, and storage temperature affect peptide integrity far more than whether the label says "BPC 157" or "BPC-157." We verify every batch with mass spectrometry and HPLC testing to confirm the sequence matches the Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val standard, regardless of how the name is formatted on the vial.

Mechanism of Action: How BPC 157 Functions in Research Models

BPC 157 demonstrates cytoprotective and regenerative effects across multiple tissue types in preclinical models, with proposed mechanisms involving growth factor modulation, angiogenesis promotion, and nitric oxide pathway regulation. Animal studies published in peer-reviewed journals—including the Journal of Physiology-Paris and the European Journal of Pharmacology—report accelerated wound healing, tendon-to-bone reconnection, and gastric ulcer resolution following systemic or localized BPC 157 administration. The peptide appears to upregulate vascular endothelial growth factor (VEGF) expression, increasing capillary density in damaged tissue and improving nutrient delivery during repair phases.

The nitric oxide (NO) pathway represents another key mechanism. BPC 157 has been shown to modulate NO synthase activity in vascular endothelium, which influences blood flow, inflammation response, and tissue oxygenation. In rat models of ligament injury, systemic BPC 157 administration resulted in faster collagen deposition and tensile strength recovery compared to saline controls—a finding published in the Journal of Orthopaedic Research. Importantly, these effects occurred whether researchers labeled the compound "BPC 157" or "BPC-157" in their protocols, because the molecular identity remained constant.

Half-life and dosing protocols vary across studies, but the peptide demonstrates stability in both subcutaneous and intraperitoneal administration routes. Research doses typically range from 10 mcg/kg to 10 mg/kg body weight in animal models, administered once or twice daily depending on the injury model. The compound does not bind to known growth hormone secretagogues or GLP-1 receptors—its mechanism is distinct from peptides like Ipamorelin or GLP-1 agonists. For researchers exploring regenerative pathways beyond incretin-based compounds, BPC 157 offers a mechanistically unique profile rooted in gastric cytoprotection rather than metabolic signaling.

Common Formulation and Storage Considerations

BPC 157 is supplied as lyophilized powder requiring reconstitution with bacteriostatic water before use in research protocols. The lyophilized form remains stable at −20°C for extended periods—typically 12–24 months when stored in sealed vials away from light and humidity. Once reconstituted, the peptide solution must be refrigerated at 2–8°C and used within 28 days to maintain structural integrity. Temperature excursions above 8°C cause irreversible degradation of the peptide backbone, rendering the compound inactive regardless of whether the vial label says "BPC 157" or "BPC-157."

Reconstitution technique matters more than most researchers expect. Injecting air into the vial while drawing bacteriostatic water creates positive pressure that can force contaminants back through the needle on subsequent draws—a procedural error we've observed across hundreds of research inquiries. The correct method: inject the bacteriostatic water slowly along the inside wall of the vial, allow it to dissolve naturally without shaking, and never inject air into a peptide vial. Shaking or vigorous agitation denatures the peptide structure, breaking hydrogen bonds that stabilize the 15-amino-acid chain.

Purity verification is non-negotiable when sourcing BPC 157. High-purity peptides—98% or greater as verified by HPLC—contain minimal truncated sequences or synthesis byproducts that could interfere with research outcomes. At Real Peptides, every batch undergoes mass spectrometry to confirm the Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val sequence matches the published standard. We also offer BPC 157 Capsules for oral administration research protocols, though subcutaneous injection remains the predominant route in published studies. Storage, reconstitution, and purity—not the hyphen—determine whether your research compound performs as expected.

BPC 157 vs BPC-157: Naming Variations Across Suppliers

The table below compares how different naming conventions appear across research literature, commercial suppliers, and regulatory filings—demonstrating that the hyphen signals formatting preference, not molecular difference.

Some suppliers use "BPC-157" exclusively because it appears more frequently in recent PubMed-indexed studies—purely a search optimization tactic. Others maintain "BPC 157" to align with the original Zagreb publications from the 1990s. Neither choice indicates higher purity, better synthesis, or superior research outcomes. What does matter: whether the supplier can provide third-party HPLC verification of the 15-amino-acid sequence and confirm storage at −20°C before shipment. A supplier offering "BPC-157" at 95% purity is objectively inferior to one offering "BPC 157" at 98% purity, regardless of hyphen presence.

Key Takeaways

• BPC 157 and BPC-157 are identical—the hyphen represents formatting preference, not a molecular or functional difference.
• The peptide is a synthetic 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from Body Protection Compound found in human gastric juice.
• Published research uses both naming conventions interchangeably without distinguishing between them in methodology or results sections.
• Purity, storage temperature, and reconstitution technique determine peptide integrity—not whether the label includes a hyphen.
• The "157" designation is a catalog number from the original Zagreb research series, not a molecular weight or fragment position.
• Mass spectrometry and HPLC testing verify sequence accuracy regardless of how the compound name is formatted on commercial labeling.

What If: BPC 157 Scenarios

What If a Supplier Claims BPC-157 Is Newer or More Potent Than BPC 157?

Treat this as a red flag—it signals either a fundamental misunderstanding of peptide chemistry or deliberate misrepresentation. The amino acid sequence, synthesis pathway, and research profile are identical whether written with or without a hyphen. A supplier making this claim likely sources from contract manufacturers without verifying batch composition, or uses marketing tactics to differentiate commodity peptides. Request third-party HPLC and mass spectrometry data showing the exact sequence; any legitimate supplier will provide this documentation within 24–48 hours.

What If Research Protocols Reference BPC 157 But Your Supplier Only Stocks BPC-157?

Proceed with confidence if the supplier can verify the 15-amino-acid sequence matches published standards. The naming inconsistency will not affect experimental outcomes, provided purity is ≥98% and storage conditions were maintained at −20°C before shipment. Cross-reference the supplier's certificate of analysis (CoA) against the Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val sequence—if it matches, the hyphen is irrelevant. If the supplier cannot produce a CoA or provide HPLC verification, source elsewhere regardless of how the name is written.

What If You're Comparing BPC 157 Studies and Half Use Different Names?

Extract dosing, administration route, and purity data rather than fixating on naming format. Studies published in the Journal of Physiology-Paris and European Journal of Pharmacology use both "BPC 157" and "BPC-157" interchangeably without protocol differences. What matters for reproducibility: dose in mcg/kg, injection frequency, reconstitution vehicle (bacteriostatic water vs saline), and storage conditions. The hyphen appears or disappears based on journal style guides, not experimental design. Focus on methodology sections, not title formatting, when designing research protocols.

The Definitive Truth About BPC 157 vs BPC-157

Here's the honest answer: the hyphen is meaningless. BPC 157 and BPC-157 describe the exact same 15-amino-acid synthetic peptide with the same cytoprotective mechanism, the same dosing profiles in research models, and the same chemical stability requirements. The naming variation persists because early researchers didn't standardize formatting, and commercial suppliers copied whichever version appeared in the studies they cited. This isn't like comparing semaglutide to tirzepatide—those are structurally distinct molecules with different receptor targets. BPC 157 and BPC-157 are identical at the molecular level.

If a supplier, influencer, or research forum suggests otherwise—claiming one version is "stronger," "more bioavailable," or "clinically superior"—they are either uninformed or deliberately misleading. The only factors that differentiate one vial of BPC 157 from another are synthesis quality, purity percentage, storage integrity, and chain-of-custody documentation. A 98% pure batch stored at −20°C outperforms a 95% pure batch stored at room temperature every single time, regardless of whether the label says "BPC 157" or "BPC-157." The hyphen doesn't protect peptides from heat, prevent degradation, or improve research outcomes. Purity and handling do.

The persistence of this question reveals a deeper issue: most peptide buyers don't know how to evaluate supplier credibility. They assume naming differences signal product differences because that's true for most supplement categories—whey isolate vs concentrate, creatine monohydrate vs HCL, omega-3 vs omega-6. Peptides don't work that way. The amino acid sequence is the product. If the sequence matches the published standard and purity testing confirms ≥98% composition, you have the compound the research describes. If those two criteria aren't met, the name on the label—hyphen or not—means nothing. At Real Peptides, we provide both HPLC and mass spectrometry verification with every order because sequence accuracy is the only metric that matters. The hyphen is typography; the 15 amino acids are chemistry.

Sourcing peptides for serious research requires looking past surface-level naming conventions and verifying what actually determines compound integrity: synthesis method, purity, storage, and third-party testing. Whether you write "BPC 157" or "BPC-157" in your lab notes is irrelevant—what you inject into your research model is the only thing that counts. Verify the sequence, confirm the purity, and ignore the hyphen. That's the definitive truth.

BPC 157 and BPC-157 will continue to appear interchangeably in literature, supplier catalogs, and research forums—not because they're different, but because no regulatory body or industry consortium has mandated standardization. Until that happens, focus on what peptide chemistry actually depends on: the exact amino acid sequence, verified purity, and proper storage from synthesis to reconstitution. The hyphen is a distraction; the molecule is what matters.